Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kala Bio Inc (NQ: KALA )

9.510 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.510
Bid (Size) 3.830 (1)
Ask (Size) 14.30 (5)
Prev. Close 9.510
Today's Range 9.510 - 9.510
52wk Range 3.544 - 56.72
Shares Outstanding 2,542,716
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire

Performance

YTD
-70.23%
-70.23%
1 Month
-28.92%
-28.92%
3 Month
-40.93%
-40.93%
6 Month
-39.50%
-39.50%
1 Year
-16.76%
-16.76%

More News

Read More
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
Kala Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Where Kala Pharmaceuticals Stands With Analysts
Via Benzinga
KALA BIO to Participate in Upcoming Investor Conferences in August
From KALA BIO, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Name Change to KALA BIO
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Aeglea Biotherapeutics, Toro Corp, AirSculpt, A Company Moves Up 4,166 Positions & More
Via Benzinga
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Toro Corp, PaxMedica, Getty Images And More
Via Benzinga
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
5 Short Squeeze Stocks To Watch: Getty Images, Bullfrog AI And A New Leader For The Week
Via Benzinga
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Getty Images, Guardforce AI And 2 Stocks Moving Up Over 1,000 Positions On The Leaderboard
Via Benzinga
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More
Via Benzinga
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Short Interest Sector Focus: Healthcare Sector
Via Benzinga
5 Short Squeeze Stocks To Watch: Unicycle Therapeutics, Getty Images And More
Via Benzinga
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
10 Short Squeeze Candidates: Unicycle Therapeutics, Compass Pathways, Virgin Orbit Among Those To Watch
Via Benzinga
Kala Pharma Reveals Safety Data From Stem Cell Therapy Trial For Corneal Defect Impacting Around 240K People In Developed Nations
Via Benzinga
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.